Nanotherapeutic intervention promotes blood-spinal cord barrier repair in spinal cord injury, indicating potential for enhanced treatment.
As a severe and disabling central nervous system disorder, spinal cord injury (SCI) remains challenging, partly because of the difficulty in addressing secondary injury caused by the blood-spinal cord barrier (BSCB) disruption. As the neurovascular unit's crucial component, the BSCB regulates the homeostasis of the spinal cord. Inspired by the established protective effect of H₂S in pan-vascular pathologies, we engineered an intravenously administered nanoparticle SPRC@MPDA-RGD. By utilizing the overexpression of αvβ₃ integrin on endothelial cells after SCI, the functionalized peptide c(RGDyK) can guide SPRC@MPDA-RGD for precise delivery to the BSCB. The MPDA scaffold has the ability to both deliver S-propargyl-cysteine (SPRC) and scavenge reactive oxygen species (ROS). Subsequently, the release of SPRC upregulates cystathionine γ-lyase (CSE) and stimulates endogenous H₂S production in injured endothelial cells, thereby protecting the BSCB. We also investigated the biological mechanisms underlying the therapeutic effects of SPRC@MPDA-RGD. The production of H₂S in endothelial cells activates the PI3K/Akt/mTOR pathway, which subsequently suppresses ferritinophagy, reduces ferritin degradation, and ultimately suppresses ferroptosis. In summary, our work proposes a nanotherapeutic strategy that coordinates H₂S production and ROS scavenging to inhibit ferritinophagy, thereby promoting BSCB repair, showing significant potential in promoting SCI treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: